Perjeta: new option for HER2-positive breast cancer

Perjeta (pertuzumab) is licensed for HER2-positive metastatic or locally recurrent unresectable breast cancer in patients who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease, in combination with trastuzumab and docetaxel.

Perjeta (pertuzumab) and Herceptin (trastuzumab) used together produce a more comprehensive blockade of HER2 signalling and thus greater antitumour activity than either agent used alone
Perjeta (pertuzumab) and Herceptin (trastuzumab) used together produce a more comprehensive blockade of HER2 signalling and thus greater antitumour activity than either agent used alone

PHARMACOLOGY 

Pertuzumab, a monoclonal antibody, targets the extracellular dimerization domain of the human epidermal growth factor 2 (HER2) protein but at a different subdomain to trastuzumab. It inhibits ligand-initated intracellular signalling, resulting in cell growth arrest and apoptosis.1

CLINICAL STUDIES

Pertuzumab was investigated in the pivotal randomised, double-blind, placebo-controlled phase III trial CLEOPATRA in 808 patients with HER2-positive metastatic or locally recurrent unresectable breast cancer.1,2

Patients given pertuzumab, in combination with trastuzumab and docetaxel, had a median progression-free survival of 18.5 months compared with 12.4 months for those in the placebo arm (HR=0.62, 95% CI 0.52–0.75; p<0.0001).2

The most common adverse reactions reported were diarrhoea, alopecia and neutropenia.1,2

 REFERENCES

  1. Perjeta Summary of Product Characteristics, March 2013
  2. Baselga J et al. N Engl J Med 2012; 366: 109-19.

View Perjeta drug record

Further information: Roche

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more